Facts
as of Nov 15, 2026
Autolus is a CAR T cell therapy company which develops advanced autologous T cell therapies that have the potential to deliver life-changing benefits to patients with cancer and autoimmune diseases.
It is hiring: 7 open roles, 1 of them posted in the last 30 days.
- Headquarters
- London, United Kingdom
- Founded
- 2014
- Employees
- 501-1000estimated range
- Open roles
- 7 in 4 citiesAlion job postings
- Website
- autolus.com
As of Nov 15, 2026, Alion lists 7 open roles at Autolus. Autolus is headquartered in London, United Kingdom. It was founded in 2014. The latest round is Venture - Series Unknown of $200M, announced in 2024.
Sources: company registers, GLEIF, Wikidata, the company's site, Alion job postingsReport a mistake
What the registers and the postings say about this employer.
Sanctions lists
OFAC SDN, EU consolidated
No match
Phishing reports
OpenPhish, Phishing.Database
None
Layoff notices
US WARN notices on file
None
Sources: company registers, the Alion truth index, OFAC and EU sanctions lists, US WARN notices
Hiring slowly: few roles were posted lately.
Leadership is the largest family, 20 of open roles.
1Posted in 30 days14% of open roles are fresh
71%Remote roles5 of 7
4Hiring offices
Can they hire you from United States?by your location
Likely
1 open roles are in your country: you apply locally, no move needed.
United Kingdom11On site
United States1On site
Remote, from elsewhere5Rare
No posting offers visa sponsorship. Remote roles: 5.
Time to fillmedian days to close a role
Autolus45 days
Market, same roles32 days
Alion signals0-100
Demand22
Pay19
Your chance25
How badly they need people, whether they pay, how realistic getting in is.
Open roles over time−100%
Oct 5This week
Open roles a week: 10 then, 0 now
Where the openings areshare of open roles · trend
Leadership20▲
Sales20▲
Industrial Engineering13▼
QA7▲
Finance7▼
Operations7▼
Newest roles
Data Solution Architect≈ $93k – $164k per year (Estimated) · Hybrid · Full-Time · 10+ years exp · Bachelor's Degree · London
What postings ask forlanguages named in open roles
Degree asked
Bachelor's Degree 67%Master's Degree 17%Doctoral Degree (PhD) 17%
6 postings state a degree.
Benefits named in postingsshare of open roles
Health insurance229%
Professional development114%
Life insurance114%
Contract type
Full-Time 7
Visa sponsorship: none statedRelocation: none stated
Source: the company's careers site, read by Alion several times a day; market medians from all open roles of the same family
Footprint
Hiring in 4 cities in 2 countries.
4Cities
2Countries
LondonBusiest site
Source: office addresses in postings and company registers
Financials
Funding rounds, investors and revenue on record.
$200MTotal raised
$567kPublic grants1 public grant
GrantLatest round
2Rounds and grants
Money by yearUSD, rounds and grants
2026$567k1 record
2024$200M1 record
Largest rounds and grants
Sources: funding announcements, grant and company registers
Tech stack
Technologies named in job postings at Autolus over the last 12 months, by layer, with the share of postings for each.
7Technologies in use
6Postings analysed
52/100Stack modernity
Sign in to see how your skills match this stackSign In
Source: the technologies named in the company's postings and on its site
Milestones
Each milestone is dated by its source: registers, filings, the press
Newsroom
Sep 122026
News · YahooFinance
On August 11, Autolus Therapeutics (NASDAQ:AUTL) reported second-quarter results that finally showed the kind of growth investors had been waiting years to see. Net product reven…
Sep 92026
News · markets.businessinsider.com
LONDON and GAITHERSBURG, Md., Sept. 09, 2026 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a commercial-stage biopharmaceutical c...
Sep 92026
News · RTTNews
Autolus Therapeutics plc (AUTL) today announced that the U.S. FDA has granted regenerative medicine advanced therapy (RMAT) designation to obecabtagene autoleucel (obe-cel) for t…
Jun 172026
News · YahooFinance
Autolus Therapeutics plc (NASDAQ:AUTL) is one of the small-cap stocks with potential to rise 1000 percent. Unlike many biotech companies that are still waiting for their first ap…
Jan 122026
News · Pulse 2.0
Autolus Therapeutics announced it expects preliminary unaudited net product revenue from AUCATZYL (obecabtagene autoleucel; obe-cel) of about $24 million for the fourth quarter o…
Sources: the outlets named on each headline, each story once